The latest price target for Seres Therapeutics (NASDAQ:MCRB) was reported by Canaccord Genuity on November 14, 2024. The analyst firm set a price target for $10.00 expecting MCRB to rise to within 12 months (a possible 986.96% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Seres Therapeutics (NASDAQ:MCRB) was provided by Canaccord Genuity, and Seres Therapeutics maintained their buy rating.

There is no last upgrade for Seres Therapeutics

The last downgrade for Seres Therapeutics Inc happened on October 24, 2024 when JP Morgan changed their price target from N/A to N/A for Seres Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seres Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seres Therapeutics was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Seres Therapeutics (MCRB) rating was a maintained with a price target of $10.00 to $10.00. The current price Seres Therapeutics (MCRB) is trading at is $0.92, which is out of the analyst’s predicted range.